Background:
According to the National Cancer Plan in Germany, all cancer patients should receive high-quality care in accordance with evidence-based treatment guidelines. Certification programs were established for this purpose but have not yet been comprehensively evaluated.
Methods:
In the WiZen project, which was supported by the Innovation Fund (supported project number 01VSF17020), controlled cohort studies were performed to investigate whether initial treatment in hospitals with or without a certificate from the German Cancer Society was associated with a difference in overall survival (primary endpoint) in patients with cancer of the colon, rectum, lung, pancreas, breast, cervix, prostate, endometrium, and ovary, head and neck cancer, and neuro-oncological tumors. The studies were based on nationwide data from adult insurees of the AOK statutory health insurance carrier for the years 2009-2017.
Results:
The majority of patients with all entities except breast cancer received their initial treatment in non-certified hospitals. Initial treatment in a certified hospital was found to be beneficial in terms of overall survival for all cancer entities, even after extensive adjustment for patient- and hospital-related confounders. The hazard ratio (HR) ranged from 0.97 (95% CI: [0.94; 1.00]) for lung cancer to 0.77 [0.74; 0.81] for breast cancer, corresponding to an absolute risk reduction (ARR) for overall survival of 0.62 months for lung cancer to 4.61 months for cervical cancer.
Conclusion:
The WiZen study shows for the entities studied that initial cancer treatment in a certified center is associated with lower mortality. Despite the recommendations of the National Cancer Plan, however, more than 40% of all cancer patients still receive their initial treatment in a non-certified hospital. The preferential provision of initial care in certified hospitals would be likely to improve overall survival. Although the study design does not permit any conclusion with regard to causality, the findings seem robust considering that a control group was used, confounders were taken into account, and the study population was of large size.
Citing Articles
Treatment Quality of Rectal Cancer Patients in Certified Colorectal Cancer Centers Versus Non-Certified Hospitals: A Comparative Analysis.
Mroczkowski P, Kusian H, Jannasch O, Lippert H, Zajdel R, Zajdel K
Cancers (Basel). 2025; 17(1.
PMID: 39796747
PMC: 11720547.
DOI: 10.3390/cancers17010120.
Course of Mental Disorders in Early Cancer Survivorship in Relation to Socioeconomic Status: A Multi-Center Prospective Longitudinal Study (LUPE).
Springer F, Goerling U, Zimmermann T, Ernst J, Engel C, Hermann M
Psychooncology. 2025; 34(1):e70059.
PMID: 39780021
PMC: 11711303.
DOI: 10.1002/pon.70059.
Multidisciplinary tumor boards in oral cavity cancer: survival effect due to balancing guideline adherence and treatment delays.
Burkhardt V, El-Shabrawi K, Riemann S, Voss P, Becker C
Front Oral Health. 2024; 5:1493319.
PMID: 39620063
PMC: 11604625.
DOI: 10.3389/froh.2024.1493319.
Quality-assured treatment in certified cancer center networks in upper Franconia, Germany: a population-centered retrospective cohort analysis based on data of the Bavarian cancer registry.
Emmert M, Gorodiscan I, Thater A, Buchner D, Kiani A, Muller-Nordhorn J
BMC Health Serv Res. 2024; 24(1):1453.
PMID: 39578869
PMC: 11583377.
DOI: 10.1186/s12913-024-11972-3.
Patient management with Head and Neck tumors-A nationwide data collection in oral and maxillofacial surgery.
Pabst A, Zeller A, Goetze E, Holzle F, Hoffmann J, Raguse J
Clin Oral Investig. 2024; 28(9):469.
PMID: 39105887
DOI: 10.1007/s00784-024-05859-0.
Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG).
Stuebs F, Beckmann M, Dannecker C, Follmann M, Nothacker M, Schnurch H
J Cancer Res Clin Oncol. 2024; 150(5):250.
PMID: 38727842
PMC: 11087317.
DOI: 10.1007/s00432-024-05769-4.
Influence of Certification Program on Treatment Quality and Survival for Rectal Cancer Patients in Germany: Results of 13 Certified Centers in Collaboration with AN Institute.
Andric M, Stockheim J, Rahimli M, Al-Madhi S, Acciuffi S, Dolling M
Cancers (Basel). 2024; 16(8).
PMID: 38672577
PMC: 11047918.
DOI: 10.3390/cancers16081496.
In Reply.
Schmitt J, Schoffer O, Klinkhammer-Schalke M
Dtsch Arztebl Int. 2024; 121(6):203-204.
PMID: 38666679
PMC: 11079799.
DOI: 10.3238/arztebl.m2023.0265.
Certification Does not Necessarily Reduce Mortality.
Frohner M
Dtsch Arztebl Int. 2024; 121(6):202-203.
PMID: 38666678
PMC: 11079800.
DOI: 10.3238/arztebl.m2023.0264.
Some Points of Criticism.
Hanisch E
Dtsch Arztebl Int. 2024; 121(6):202.
PMID: 38666677
PMC: 11079796.
DOI: 10.3238/arztebl.m2023.0263.
Treatment in Certified Breast Cancer Centers Improves Chances of Survival of Patients with Breast Cancer: Evidence Based on Health Care Data from the WiZen Study.
Schoffer O, Wimberger P, Gerken M, Bierbaum V, Bobeth C, Rossler M
Geburtshilfe Frauenheilkd. 2024; 84(2):153-163.
PMID: 38344046
PMC: 10853029.
DOI: 10.1055/a-1869-1772.
Outcomes of Multimodal Treatment in Elderly Patients with Localized Non-Small Lung Cancer from a Radiation Oncology Point of View: Special Focus on Low-Dose Cisplatin.
Alt N, Muster J, Ziegler D, Bendrich S, Donath S, Hille A
Cancers (Basel). 2024; 16(2).
PMID: 38254817
PMC: 10814481.
DOI: 10.3390/cancers16020327.
Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service Point.
Schulmeyer C, Beckmann M, Fasching P, Haberle L, Golcher H, Kunath F
Diagnostics (Basel). 2023; 13(21).
PMID: 37958196
PMC: 10647700.
DOI: 10.3390/diagnostics13213300.
[What is confirmed in the prevention, diagnostics and treatment of early breast cancer?].
Kuehnle E, Rottger M, Park-Simon T
Inn Med (Heidelb). 2023; 64(12):1154-1161.
PMID: 37902868
DOI: 10.1007/s00108-023-01619-6.
Evaluability of the Effect of Oncology Center Certification.
Stang A
Dtsch Arztebl Int. 2023; 120(39):645-646.
PMID: 37902709
PMC: 10622056.
DOI: 10.3238/arztebl.m2023.0184.